OTC:ACOGF Alpha Cognition 8/12/2024 Earnings Report Earnings HistoryForecast Alpha Cognition EPS ResultsActual EPS-C$0.01Consensus EPS -C$0.04Beat/MissBeat by +C$0.03One Year Ago EPSN/AAlpha Cognition Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAlpha Cognition Announcement DetailsQuarterDate8/12/2024TimeTASConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Alpha Cognition Earnings HeadlinesAlpha Cognition to Report First Quarter 2025 Financial Results and Operating OverviewMay 1, 2025 | financialpost.comAlpha Cognition Earnings Call: Positive Outlook Amid GrowthApril 9, 2025 | tipranks.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.May 13, 2025 | Brownstone Research (Ad)Alpha Cognition Inc. Common Stock (NASDAQ:ACOG) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.com Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating OverviewMarch 31, 2025 | financialpost.comAlpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating OverviewMarch 19, 2025 | financialpost.comSee More Alpha Cognition Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alpha Cognition? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alpha Cognition and other key companies, straight to your email. Email Address About Alpha CognitionAlpha Cognition (OTC:ACOGF), a clinical stage biopharmaceutical company, develops treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.View Alpha Cognition ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum HoldsWhy Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery?Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Upcoming Earnings JD.com (5/13/2025)NU (5/13/2025)SEA (5/13/2025)Sony Group (5/13/2025)Cisco Systems (5/14/2025)Toyota Motor (5/14/2025)Applied Materials (5/15/2025)Copart (5/15/2025)NetEase (5/15/2025)Alibaba Group (5/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
